TD Asset Management Inc Invests $1.02 Million in Immuneering Corporation $IMRX

TD Asset Management Inc bought a new position in shares of Immuneering Corporation (NASDAQ:IMRX) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 145,180 shares of the company’s stock, valued at approximately $1,016,000.

A number of other hedge funds have also modified their holdings of IMRX. Jane Street Group LLC acquired a new position in Immuneering during the first quarter valued at approximately $32,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Immuneering in the 3rd quarter valued at $35,000. Future Financial Wealth Managment LLC acquired a new stake in Immuneering during the 3rd quarter worth $35,000. Kingsview Wealth Management LLC bought a new position in Immuneering during the second quarter worth about $47,000. Finally, XTX Topco Ltd bought a new stake in shares of Immuneering in the second quarter worth about $90,000. 67.65% of the stock is currently owned by institutional investors and hedge funds.

Immuneering Trading Down 3.7%

Shares of IMRX opened at $4.98 on Friday. The company’s fifty day simple moving average is $5.25 and its 200 day simple moving average is $6.07. Immuneering Corporation has a 1-year low of $1.10 and a 1-year high of $10.08. The company has a market cap of $321.56 million, a price-to-earnings ratio of -2.80 and a beta of 0.46.

Insider Transactions at Immuneering

In related news, Director Thomas J. Schall acquired 21,645 shares of the firm’s stock in a transaction on Thursday, January 15th. The shares were purchased at an average cost of $4.67 per share, for a total transaction of $101,082.15. Following the completion of the acquisition, the director directly owned 74,530 shares in the company, valued at approximately $348,055.10. This trade represents a 40.93% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Peter Feinberg bought 20,000 shares of the stock in a transaction dated Monday, January 12th. The shares were purchased at an average price of $4.35 per share, for a total transaction of $87,000.00. Following the purchase, the director owned 135,441 shares of the company’s stock, valued at $589,168.35. This trade represents a 17.32% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders bought 51,819 shares of company stock worth $234,472. 22.90% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Chardan Capital restated a “buy” rating and set a $20.00 target price on shares of Immuneering in a report on Thursday, November 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immuneering in a report on Monday, December 29th. Finally, Wall Street Zen cut Immuneering from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Immuneering currently has a consensus rating of “Moderate Buy” and an average target price of $16.50.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.